A Phase 2 Peri-Operative Study of Treatment With Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Patients With Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)
Latest Information Update: 29 Jul 2024
At a glance
- Drugs Cemiplimab (Primary) ; Fianlimab (Primary)
- Indications Carcinoma; Skin cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
Most Recent Events
- 26 Jul 2024 Status changed from not yet recruiting to withdrawn prior to enrolment due to Business Decision .
- 22 Apr 2024 Status changed from planning to not yet recruiting.
- 16 Sep 2022 New trial record